{"abstract": "In a complicated deal, Bristol-Myers Squibb agreed late on Friday to buy Amylin Pharmaceuticals, the maker of promising new diabetes drugs.", "web_url": "https://dealbook.nytimes.com/2012/06/29/bristol-myers-and-astrazeneca-in-7-billion-deal-for-amylin/", "snippet": "In a complicated deal, Bristol-Myers Squibb agreed late on Friday to buy Amylin Pharmaceuticals, the maker of promising new diabetes drugs.", "lead_paragraph": "11:55 p.m. | Updated ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Bristol-Myers in Deal for Amylin Valued at $7 Billion", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "AMYLIN PHARMACEUTICALS INC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Bristol Myers Squibb Company", "rank": 4, "major": "N"}], "pub_date": "2012-06-30T02:29:21+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced and Andrew Pollack", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/2fb7c89f-58fc-58f7-a485-d0810b2f978e", "word_count": 776, "uri": "nyt://article/2fb7c89f-58fc-58f7-a485-d0810b2f978e"}